OncoLux

Executive Summary

OncoLux is a privately held US MedTech company developing an integrated optical theranostics platform that combines multispectral fluorescence imaging and photodynamic therapy. This technology aims to enable real-time visualization and treatment of residual cancer tissue during surgical procedures, addressing a critical unmet need in oncology surgery. The company's initial clinical focus is on advanced colorectal and lung cancers, two of the most prevalent and challenging malignancies. OncoLux's approach has the potential to improve surgical outcomes by reducing the risk of local recurrence and enabling more precise tumor resection. Founded in 2015 and based in Houston, Texas, the company operates in the AI/machine learning space, leveraging advanced imaging and therapeutic modalities. While OncoLux is still in early stages with no disclosed funding or clinical milestones, its platform represents a promising convergence of diagnostic and therapeutic capabilities in a single surgical tool.

Upcoming Catalysts (preview)

• Q4 2026Initiation of First-in-Human Clinical Trial for Colorectal Cancer40% success
• Q3 2026Series A Financing Round50% success
• Q2 2026Presentation of Preclinical Data at Major Surgical Oncology Conference70% success